Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Innovent Biologics HK$2.4 billion placement of shares
The shares are listed on the Hong Kong Stock Exchange
Option Care Health $400 million revolving credit facility
We advised the administrative agent, joint lead arranger and joint bookrunner on the facility
Atara Biotherapeutics $100 million at-the-market offering
The stock is listed on Nasdaq
Smith+Nephew acquisition of CartiHeal
We are advising Smith+Nephew on the acquisition
WuXi XDC Cayman HK$3.68 billion IPO
The shares are listed on the HKEX
Amneal Pharmaceuticals $2.35 billion term loan
We advised Amneal Pharmaceuticals on a new term loan
Mallinckrodt emerges from chapter 11
We advised an ad hoc group of first-lien noteholders
Bristol Myers Squibb $4.5 billion notes offering
The investment-grade offering comprised four tranches
Alector $125 million at-the-market offering
The common stock is listed on the Nasdaq Global Select Market
NeuroPace $50 million at-the-market offering
The stock is listed on the Nasdaq Global Market